MeiraGTx Holdings has entered into a broad strategic collaboration with Janssen Pharmaceuticals to develop and commercialize gene therapies for the treatment of inherited retinal diseases (IRDs). Under the agreement, the two companies will collaborate in the clinical development of MeiraGTx’s leading IRD pipeline, including product candidates for achromatopsia (ACHM) caused by mutations in either CNGB3 or CNGA3 and X-linked retinitis pigmentosa (XLRP). In addition, MeiraGTx and Janssen are en...